BUND FINANCE

BUND FINANCE › Stocks › ROIV

Roivant Sciences Ltd. (ROIV)

NASDAQ · Stock price, chart and technical analysis

US$38.73+0.0200 (+0.05%)

Data from Financial Modeling Prep · Nov 18, 2026, 4:00 PM New York time · may be delayed

Open the live chartSee Technicals⏱ Analyze entryQuarterly earnings📅 See in calendar💬 Explain this move⇄ ComparePractice in the Simulator

Key stats

Previous closeUS$38.71
OpenUS$38.47
Day rangeUS$38.29 – US$39.24
52-week rangeUS$19.96 – US$42.50
Market capUS$28.06B
Volume3.72M
50-day averageUS$37.32
200-day averageUS$32.48
Beta1.20

Quick technical read

This describes price action; it is not a recommendation. The app also calculates RSI, MACD, the entry setup and 30+ indicators. How we calculate it

Fundamentals Annual

Fiscal year20212022202320242025
RevenueUS$55.3MUS$31.5MUS$32.7MUS$29.1MUS$8.3M
Net income−US$845.3M−US$1.0BUS$4.3B−US$172.0M−US$299.8M
EPS (diluted)-1.26-1.425.23-0.24-0.43
Gross margin83.8%90.4%95.1%96.9%84.4%
Operating margin-2,191.8%-2,565.9%-2,521.7%-3,833.3%-15,560.6%
Net margin-1,528.9%-3,200.2%13,294.2%-592.0%-3,629.2%
Free cash flow−US$695.2M−US$856.1M−US$766.7M−US$844.1M−US$758.6M
Total debtUS$283.9MUS$481.4MUS$499.7MUS$100.2MUS$107.4M
CashUS$2.1BUS$1.7BUS$6.5BUS$2.7BUS$1.4B

Compound annual growth: revenue -37.8% · net income — (4 years).

Valuation: today, its history and its sector

Today5-year averageSector median (Healthcare)
P/E—1.9x27.1x
EV / EBITDA—0.5x16.5x
Operating margin-3,233.0%—3.6%
Net margin-838.2%—-0.0%
Debt / equity0.09—0.58

Source: annual financial statements from Financial Modeling Prep. “Today” uses the current price and the last 4 quarters. The sector median uses U.S. companies above US$300M market cap. A multiple above or below its history or sector is not a recommendation.

About Roivant Sciences Ltd.

SectorHealthcare
IndustryBiotechnology
CountryGB
CEOMatthew Gline
Employees721
IPO date2020-12-08

Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bac…

roivant.com

Other stocks on BUND FINANCE

Not financial advice. BUND FINANCE publishes general information for educational purposes. Investing involves risk, including loss of capital. Legal notice